drugset
drugset / Trial / NCT04102943

Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients.

NCT04102943 ↗

Phase 4 Completed 128 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and tolerability of Tacrolimus tablet(TacroBell) in kidney transplant recipients.

Timeline

Start
2017-11-30
Primary completion
2020-09-29
Completion
2020-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.1 mg/kg Oral

Indications

No indication recorded.